MTOR and nonpapillary renal cell carcinoma: Among these inhibitors, A939572 proved efficient to reduce ccRCC cell growth in vitro, and in an in vivo mouse model, the combination of A939572 plus the mTOR inhibitor (temsirolimus) exerted a synergistic effect on tumor size reduction [121].